ASCO 2020: Lung Cancer
Filter Results
Addition of Durvalumab to Platinum + Etoposide in Extensive-Stage SCLC
Updated results from the CASPIAN study support the addition of durvalumab to platinum and etoposide as a new standard of care in extensive-stage small cell lung cancer (ES-SCLC).
Survivors of Childhood Malignancies Face Risk of Developing Lung Cancer
A recent study showed that childhood cancer survivors are at an increased risk for lung cancer.
Chemo/immunotherapy Combo Promising for Treatment of Mesothelioma
Inoperable malignant pleural mesothelioma is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.
Pembrolizumab + Chemo Continues to Improve Efficacy in Metastatic Nonsquamous NSCLC
With longer follow-up, pembrolizumab plus chemotherapy continued to improve efficacy outcomes in previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) over placebo and chemotherapy, with a manageable toxicity profile, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 9582).
Immunotherapy Combo Plus Chemo Improves Survival in First-Line NSCLC
Findings from the phase III CheckMate-9LA trial demonstrated that nivolumab plus ipilimumab, given concomitantly with 2 cycles of chemotherapy, had a statistically significant and clinically meaningful survival benefit as a first-line treatment of metastatic non-small cell lung cancer (NSCLC).
Pembrolizumab Plus Chemo Improves Survival in Extensive-Stage Small-Cell Lung Cancer
First-line pembrolizumab plus etoposide significantly improved progression-free survival (PFS) and prolonged overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) when compared to placebo plus etoposide, according to data presented during an oral presentation at the ASCO 2020 Annual Meeting (Abstract 9001).
Survival Benefit of Nivolumab + Ipilimumab in NSCLC
Findings from the 3-year follow-up of the phase III CheckMate-227 Part 1 trial demonstrate that first-line nivolumab plus ipilimumab offers sustained improvements in overall survival (OS) for patients with metastatic non-small cell lung cancer (NSCLC).
Smoking Cessation Prior to Lung Cancer Diagnosis Can Improve Survival
New research shows that individuals who quit smoking at any time—even less than 2 years prior to a lung cancer diagnosis—improve their odds of survival, according to data presented during the 2020 ASCO Annual Meeting (Abstract 1512).
Adjuvant Osimertinib Delays Recurrence in Localized NSCLC
Data from a phase III study demonstrated that treatment with osimertinib following surgery for localized non-small cell lung cancer (NSCLC) with an EGFR mutation significantly improved disease-free survival (DFS).